Lts Lohmann Therapie-Systeme Ag

Gruenenthal Gmbh

Grunenthal Gmbh

Patrick Mohr

René Eifler

Olga Bourquain

René Rietscher

Michael Horstmann

Regine Kaufmann

Walter Müller

Mohammad Sameti

Marco Emgenbroich

Karin Ludwig

Gabriel Wauer

Eric Galia

Nico Reum

Peter Klaffenbach

Tobias Kleudgen

Jan Stampfuss

Christian Hausen

Wolfgang Prange

Stefan Buller

Klaus Pusecker

Susanne Stoelben

Hans-Werner Wolf

Eva-Marie Prinz

Stefan Lorscheidt

The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure comprising a therapeutically effective amount of asenapine, said self-adhesive layer structure comprising: A) a backing layer; B) an asenapine-containing layer comprising: 1. asenapine in the form of the free base; and 2. a polymer selected from the group consisting of polysiloxanes and polyisobutylenes in an amount of more than 50% by weight based on the total weight of the asenapine-containing layer; and C) optionally an additional skin contact layer.

Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Transdermal therapeutic system containing asenapine

Adhesive bandages are provided with a water-vapor permeable back layer and an adhesive layer, in which the adhesive layer includes 10 weight percent of a disperse internal phase of hydrophilic particles that are water-swellable in an outer phase that includes at least 10 weight percent of a styrene block copolymer and at least 20 weight percent of an ester resin of colophony, and that can further contain at least one anti-virus substance.

Water-vapor-permeable adhesive bandages

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising an asenapine-containing layer structure, said asenapine-containing layer structure comprising A) a backing layer and B) an asenapine-containing layer, wherein the transdermal therapeutic system comprises a silicone acrylic hybrid polymer.

Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer

The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.

Transdermal administration of memantine

A transdermal therapeutic system with a system support, at least one advancing element which is embedded into the system support, and at least one active ingredient reservoir which can be elastically deformed at least in some regions and which is embedded into the advancing element. On the application side of the transdermal therapeutic system, the system support surrounds the advancing element, and the advancing element surrounds the active ingredient reservoir. The advancing element comprises a swelling body which can be expanded by means of a liquid intake. The system support is designed to be rigid at least in some regions. A transdermal therapeutic system is developed which enhances the effect of the advancing element.

Transdermal therapeutic system with pressure generating device

The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.

Transdermal therapeutic system having controlled active substance flow comprising a basic reacting oxide

Transdermal or topical plasters containing active ingredient are provided that include a non-occlusive back layer, a matrix formed from of one or more polymer layers having at least one pharmaceutical active ingredient in one or more of the layers, in which the structure-forming base polymers of the layer(s) are non-occlusive or only slightly occlusive and a second polymer that has a low water-vapor permeability and that is immiscible or only very slightly miscible with the base polymer is dispersed in at least one of the polymer layers.

Plaster having adjustable occlusion

The invention relates to a transdermal therapeutic system made of the following layers: a carrier layer (T), an active ingredient layer (R), a membrane layer (M) and optionally an adhesive layer (K), wherein the carrier layer (T) is impenetrable to the active substance and to water, the active substance layer (R) comprises as an active substance component the salt of an alkali reactive active substance, such as a CNS-active amine in combination with at least one alkali reactive further component, and a polymer component (P1), wherein the active substance is released from the active substance layer (R) only by the moisture entering from the exterior through the membrane layer (M), and the membrane layer (M) is made of a polymer component (P2), allowing a uniform delivery of basic active substances to the skin.

Transdermal therapeutic system having stabilized membrane

Growing community of inventors

Bad Breisig, Germany

Patrick Mohr